Search

Displaying results 3151 - 3160 of 7452 in total
  1. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

  2. Drug

    Octopamine

    go.drugbank.com/drugs/DB13251
    Experimental

    It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.

  3. Target

    Retinol dehydrogenase 8

    go.drugbank.com/bio_entities/BE0002323
    TargetHumans

    Retinol dehydrogenase with a clear preference for NADP. Converts all-trans-retinal to all-trans-retinol. May play a role in the regeneration of visual pigment at high light intensity (By similarity)

    Synonyms: Photoreceptor outer segment all-trans retinol dehydrogenaseFunction: all-trans-retinol dehydrogenase (NAD+) activity
  4. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    A second focus was on the sequence Lys-Pro-Val (11-13) that is known to be important for antimicrobial activity. … understand the candidacidal activity of derivatives of alpha-MSH have focused on the alpha-MSH amino acid sequence (6-13), which contains the invariant core sequence His-Phe-Arg-Trp (6-9) that is important for

  5. Drug

    Chlormerodrin

    go.drugbank.com/drugs/DB00534
    ApprovedWithdrawn

    The radiolabeled form has been used as a diagnostic and research tool. It is no longer used and has been replaced with new classes of diuretic drugs.

  6. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity for … [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

  7. Drug

    Thonzonium

    go.drugbank.com/drugs/DB09552
    Approved

    Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promotin...

  8. Drug

    Lifitegrast

    go.drugbank.com/drugs/DB11611
    ApprovedInvestigational

    Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Fenspiride

    go.drugbank.com/drugs/DB08979
    Investigational

    ), as well as for maintenance treatment of asthma. … It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis

    Categories: Drugs for Obstructive Airway Diseases
  10. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market